Search jobs 20-Apr-2021 Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
Half of All Patients With NSCLC Have Oncogene Mutations, Yet Many Patients Are Not Tested to Screen for Biomarkers
Professional Clinical Guidelines Recommend Broad Biomarker Testing for Actionable and Emerging Biomarkers, Including KRAS
Biomarker Assist™ May Provide Eligible Patients Savings on Biomarker Testing
Amgen (NASDAQ: AMGN) today announced the launch of Biomarker Assist™, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist™, eligible patients may save on biomarker testing.
Radiology and Radiation Oncology | Imaging Technology News
itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
Physician and Patient Groups Call On CMS to Update Medicare Lung Cancer Screening Coverage
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.